Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Generation Study 1
NCT02565511Phase 3Terminated
- Sponsor
- Novartis
- Start
- Nov 2015
- Primary completion
- Apr 2020
- Modality
- Recombinant Protein Vaccines, Peptide-based Cancer Vaccines, Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial of amilomotide and umibecestat in Alzheimer's disease (AD) (4 cohorts), sponsored by Novartis. Primary endpoints: Time to Event (Diagnosis of Mild Cognitive Impairment or Dementia, Due to Alzheimer's Disease) and Alzheimer's Prevention Initiative Composite Cognitive Test Score. Started Nov 2015; status: terminated.
02
Drugs
amilomotideumibecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02565511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02565511.